| Quote
: |
刘静,王昕.润燥止痒胶囊、依巴斯汀片联合干扰素凝胶治疗慢性湿疹的疗效及对生活质量的影响[J].湖南中医药大学学报英文版,2018,38(10):1173-1178.[Click to copy
] |
|
| |
|
|
| This paper
：Browser 2527times Download 1391times |
| 润燥止痒胶囊、依巴斯汀片联合干扰素凝胶治疗慢性湿疹的疗效及对生活质量的影响 |
| 刘静,王昕 |
| (清华大学附属第一医院皮肤性病科, 北京 100016) |
| 摘要: |
| 目的 对润燥止痒胶囊、依巴斯汀片联合干扰素凝胶治疗慢性湿疹的临床疗效进行研究，并对患者的生活质量进行评价。方法 将本院收治的63例慢性湿疹患者按随机数字表法分为对照组31例和治疗组32例，对照组患者给予依巴斯汀片口服及醋酸曲安奈德乳膏外用治疗，治疗组患者则给予润燥止痒胶囊、依巴斯汀片口服及重组人干扰素α2b凝胶外用治疗，疗程4周。比较两组患者治疗前后的症状分级量化积分、T淋巴细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+）检测结果、血清相关指标（TNF-α、IFN-γ、IL-10、IL-18、总IgE）水平等，并比较两组患者的临床疗效、不良反应发生和随访复发情况，以及生活质量评价。结果 治疗组患者治疗后的各症状分级量化积分、T淋巴细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+）检测结果、血清相关指标（TNF-α、IFN-γ、IL-10、IL-18、总IgE）水平等与对照组治疗后比较差异均有统计学意义（P<0.05）。治疗组患者的临床疗效总有效率显著高于对照组（93.7% vs74.2%，P<0.05）。两组患者治疗期间的不良反应发生率差异无统计学意义（P>0.05），且治疗组治疗后随访3个月的疾病复发率显著低于对照组（P<0.05）。治疗组的生活质量的EQOLS各维度评分及总评分均显著低于对照组（P<0.05）。结论 润燥止痒胶囊、依巴斯汀片联合干扰素凝胶治疗慢性湿疹能显著提高临床疗效，明显改善患者症状、T淋巴细胞亚群及血清相关指标水平，且复发率低，能有效提升患者的生活质量。 |
| 关键词: 慢性湿疹 润燥止痒胶囊 依巴斯汀片 重组人干扰素α2b凝胶 临床疗效 生活质量 |
| DOI：10.3969/j.issn.1674-070X.2018.10.019 |
| Received:April 12, 2018 |
| 基金项目:清华大学自主科研计划资助项目（20141081271）。 |
|
| Clinical Efficacy and Life Quality of Runzao Zhiyang Capsule and Ebastine Tablets Combined with Interferon Gel in the Treatment of Chronic Eczema |
| LIU Jing,WANG Xin |
| (Department of Dermatology, The First Hospital of Tsinghua University, Beijing 100016, China) |
| Abstract: |
| Objective To study the clinical efficacy of Runzao Zhiyang Capsule and ebastine Tablets combined with interferon gel in the treatment of chronic eczema, and to evaluate the quality of life of patients. Methods The 63 cases of chronic eczema patients were randomly divided into the control group (n=31) and the treatment group (n=32). The patients in the control group were treated with oral treatment of ebastine Tablets and external use of triamcinolone acetonide acetate Cream, and the patients in the treatment group were treated with oral treatment of Runzao Zhiyang capsule and ebastine Tablets, and external use of human recombinant α2b interferon gel, and the course was for 4 weeks. The symptom classification of quantitative scores, the detection results of T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) and the level of serum related index (TNF-α, IFN-γ, IL-10, IL-18, total IgE) of two groups were compared before and after treatment. The clinical efficacy, adverse reactions, disease recurrence and quality of life in the two groups were compared. Results The symptom classification of quantitative scores, the detection results of T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) and the level of serum related index (TNF-α, IFN-γ, IL-10, IL-18, total IgE) in the treatment group after treatment were significantly different from those in the control group after treatment (P<0.05). The total effective rate of the treatment group was significantly higher than that of the control group (93.75% vs 74.19%, χ2=4.510, P=0.034). There was no significant difference in the incidence of adverse reactions between two groups during the treatment (P>0.05). The recurrence rate of the disease in the treatment group after 3 months of follow-up was significantly lower than that of the control group (P<0.05). The quality of life EQOLS score in the treatment group after treatment was significantly lower than the control group (P<0.05). Conclusion Runzao Zhiyang Capsule and ebastine Tablets combined with interferon gel in the treatment of chronic eczema can significantly improve the clinical efficacy, the patient's symptoms, T lymphocyte subsets and serum related indexes. The therapy has a low recurrence rate and can effectively improve the quality of life of the patient. |
| Key words: chronic eczema Runzao Zhiyang Capsule ebastine Tablets human recombinant α2b interferon gel clinical efficacy quality of life |
|
二维码（扫一下试试看！） |
|
|
|
|
